IRadimed Corporation (Nasdaq: IRMD) — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This filing reports full-year results; the supplied text does not provide standalone fourth-quarter results.
Business context
IRadimed develops, manufactures and sells MRI-compatible medical devices, related disposables and services. Its principal products are the MRidium IV infusion pump system and the 3880 patient vital signs monitor; it also sells a ferromagnetic detection system. Sales are primarily to hospitals and acute-care facilities, through a U.S. direct sales force and international distributors. The company reported an installed base of 7,196 infusion pump systems and 2,166 monitoring systems at year-end.
Financial results and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $65.6 million | $53.3 million | +23.0% |
| Gross profit / margin | $50.2 million / 76.5% | $41.3 million / 77.4% | Profit +21.5%; margin down 0.9 percentage points |
| Operating income / margin | $20.0 million / 30.5% | $15.6 million / 29.3% | Income +28.2% |
| Net income | $17.2 million | $12.8 million | +34.0% |
| Diluted EPS | $1.35 | $1.02 | +32.4% |
| Cash from operations | $13.5 million | $10.0 million | +$3.4 million |
- Revenue growth reflected higher device sales, particularly infusion pumps, and growth in disposable, service and other revenue. U.S. revenue rose 19.7% to $52.5 million; international revenue rose 38.6% to $13.0 million.
- Device revenue increased 25.9% to $46.0 million. Extended-warranty amortization revenue decreased 7.5% to $2.0 million.
- Gross margin declined despite higher sales. Management cited higher selling prices and favorable overhead absorption, offset by inflation-related raw-material costs.
- General and administrative expense rose 41.4% to $15.1 million, mainly from legal and professional, regulatory consulting, payroll and benefits costs. Sales and marketing expense decreased 4.3% to $12.1 million; research and development expense rose 25.5% to $2.9 million.
- Cash and cash equivalents were $49.8 million at year-end, versus $58.0 million a year earlier. Working capital was $59.7 million, down from $68.9 million; stockholders’ equity was $71.4 million. The balance sheet reports no borrowings or debt; operating lease liabilities totaled approximately $2.0 million.
- Investing cash outflow was $8.0 million, including property and equipment purchases and land acquisition. Financing cash outflow was $13.7 million, primarily dividends and taxes on net share settlements. Inventory increased to $12.8 million from $5.4 million.
Material changes, outlook and notable items
- The company bought approximately 26.5 acres in Orange County, Florida, for $6.2 million to support a planned expanded office, assembly and warehouse facility. Property and equipment, net, increased to $9.3 million from $2.4 million.
- In 2023, IRadimed paid a $1.05-per-share special dividend. In December it declared a further $0.48-per-share special dividend and began a $0.15-per-share quarterly dividend; the combined $8.0 million payment was made January 12, 2024.
- Management stated that cash, operating cash flow and available financing were expected to fund projected requirements for at least 12 months from issuance of the financial statements. The supplied filing text does not give a numerical 2024 revenue or earnings forecast.
- The infusion pump’s ultrasonic motor is sourced from a single supplier. The supply agreement was renewed in March 2024 through March 1, 2029. The company also relies on a single Florida facility while planning its expansion.
- Key risks include dependence on a limited product range, medical-device regulation and potential FDA actions, supplier and manufacturing interruptions, competition in patient monitoring, international sales and distributor exposure, and product-liability or quality issues. The company reported that inflation had not materially affected 2023 results.
- The auditor issued an unqualified opinion on the financial statements. The audit identified extended-warranty deferred revenue as a critical audit matter, citing complexity in management’s manual calculations; the year-end balance was $4.8 million. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not express an opinion on internal-control effectiveness.
- The filing reports no legal proceeding currently believed likely to have a material adverse effect. It notes that the company lacks formal written policies and procedures for healthcare fraud-and-abuse compliance, despite training and informal oversight.
Important facts for investors to verify
- Whether device sales, especially infusion pump sales, and international growth continue, and how much recurring disposable and service revenue supports results.
- Whether the gross-margin decline and sharp increase in G&A expense persist; review the drivers of the elevated inventory balance and operating cash conversion.
- Funding, timing, construction costs and operational benefits of the planned facility, including the transition from the related-party Winter Springs lease.
- Supply continuity and pricing for the single-source pump motor, as well as progress toward regulatory certifications and approvals in the U.S. and abroad.
- Cash and investment availability after dividends and capital spending, and the board’s future dividend decisions. The filing states cash and cash equivalents of $49.8 million at year-end; investors should verify the composition of liquidity and subsequent-period balances.
- Revenue-recognition estimates for extended warranties, the $4.8 million deferred-revenue balance, and any subsequent audit, regulatory, product-quality or litigation developments.